TREATING TORTUOUS VEINS: ‘I have chosen not to treat my patients…by administering PCF’
By Eric Wellons, MD As a physician who treats patients with varicose veins, I have a variety of tools at my disposal that can relieve the significant disability brought on by the symptoms of this common vascular condition, such as achiness and a “heavy” feeling in the legs. In
BOSTON SCIENTIFIC LINES UP FINANCING FOR ITS $4B BTG ACQUISITION
Now that everyone has said yes, Boston Scientific has gone to the banks to sign a number of new lending agreements, including a large credit facility it could use to finance its $4.2 billion acquisition offer for British medical device maker BTG plc. The information, which came from recently posted
BOSTON SCIENTIFIC ACQUIRING BTG
Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders
VIVA 2018: BTG SENTRY BIOCONVERTIBLE IVC FILTER STUDY SHOWS FLAWLESS PERFORMANCE
BTG plc highlighted the presentation of the two-year results for the SENTRY Trial at the Vascular Interventional Advances (VIVA) conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, the world’s first bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism (PE) during the
POLIDOCANOL INJECTABLE FOAM: WHEN VEINS DON’T TAKE A STRAIGHT PATH
Patient presents with bilateral bulging varicosities By Ajit Naidu, MD An estimated one-third of the population in Western countries has untreated venous disease.[i] Some of these individuals have lived with debilitating symptoms of venous insufficiency for a decade or more because their primary care physicians or OB/GYNs have told
OPTALYSE PE: BTG RESULTS REINFORCE SAFETY, EFFICACY OF SHORTER, LOWER DOSE EKOS THERAPY FOR PE
BTG plc highlighted OPTALYSE PE one-year trial results, presented at the International Society on Endovascular Therapy in Florida in February. The findings confirm that bilateral pulmonary embolism (PE) patients treated in as little as two hours with a total tissue plasminogen activator (tPA) dose as low as 8mg continue to
VARITHENA IS AN ELEGANT SOLUTION FOR C6 ULCER
At 4 months post-treatment, Tom’s wound remained closed and he stated that he was very satisfied with the treatment. By Kenneth Otah, MD, MSc, FACC Patients with venous ulcers make up over up more than 70 percent of nonhealing ulcers. By the time these patients are referred to